Determination of a measure of a glycation end-product or disease state using tissue fluorescence lifetime

• US 8,238,993 B2
• Filed: 12/19/2007
• Issued: 08/07/2012
• Est. Priority Date: 04/04/2002
• Status: Expired due to Fees

• Current Assignee: Veralight, Inc. (Britannia Life Sciences, Inc.)
• Original Assignee: Veralight, Inc. (Britannia Life Sciences, Inc.)
• Inventors: Maynard, John D, Ediger, Marwood Neal
• Primary Examiner(s): WINAKUR, ERIC FRANK
• Application Number:
  US11/960,260
• Publication Number:
  US 20080097174A1
• Time in Patent Office: 1,693 Days
• Field of Search: 600/310, 600/317, 600/322, 600/473, 600/476
• US Class Current: 600/310
• CPC Class Codes: A61B 5/0059 using light, e.g. diagnosis by transillumination, diascopy, fluorescence A61B5/0093, A61B5/1455, A61B5/02416 and A61B5/0261 take precedence
• CPC Class Codes: A61B 5/0071 by measuring fluorescence emission
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: G01N 2021/6417 Spectrofluorimetric devices
• CPC Class Codes: G01N 21/6408 with measurement of decay time, time resolved fluorescence

Abstract

A method of determining a measure of a tissue state (e.g., glycation end-product or disease state) in an individual. A portion of the tissue of the individual is illuminated with excitation light, then light emitted by the tissue due to fluorescence of a chemical with the tissue responsive to the excitation light is detected. The detected light can be combined with a model relating fluorescence with a measure of tissue state to determine a tissue state. The invention can comprise measuring the fluorescence lifetime in either time-domain or frequency domain modes. The invention can also comprise a variety of models relating fluorescence to a measure of tissue state, including a variety of methods for generating such models. For example, multivariate models can be developed that relate lifetime trends of one or more constituents to increasing propensity to diabetes and pre-diabetes. Other biologic information can be used in combination with the fluorescence properties to aid in the determination of a measure of tissue state. The invention also comprises apparatuses suitable for carrying out the method, including appropriate light sources, detectors, and models (for example, implemented on computers) used to relate detected fluorescence and a measure of tissue state.

Claims

1. An apparatus for the determination of a tissue state in an individual, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, (iii) a measure of glycation end-products in tissue, and (iv) a combination of the above, comprising;

(a) an illumination subsystem;

(b) a detection subsystem; and

(c) an input system, configured to accept biologic information comprising one or more of;

gender of the individual, weight of the individual, waist circumference of the individual, history of disease of the individual'"'"'s family, ethnicity, skin melanin content, smoking history of the individual, or a combination thereof;

(d) an analysis subsystem, comprising a model relating fluorescence lifetime of the skin of an individual and the biologic information to tissue state.

2. An apparatus as in claim 1, wherein the model is determined according to:

(a) for each of a plurality of subjects;

(i) determining a fluorescence lifetime of a portion of the tissue of the subject;

(ii) acquiring biologic information of the subject; and

(iii) determining a tissue state of the subject; and

(b) applying a multivariate method to the plurality of fluorescence lifetime determinations, biologic information, and associated tissue state determinations to generate a model relating fluorescence lifetime and biologic information to tissue state.

3. An apparatus as in claim 1, wherein the illumination subsystem comprises means for illuminating with a short pulse of the excitation light source and the detection subsystem comprises means for measuring the fluorescence lifetime by recording the time signature of the fluorescence decay.

4. An apparatus as in claim 1, wherein the illumination subsystem comprises means for illuminating with a modulation of the excitation light and the detection subsystem comprises means for detecting the fluorescence lifetime by recording the amplitude and phase shift of the fluorescence relative to the excitation modulation.

5. A method according to claim 1, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, and (iii) a combination of the above.

6. A method of determining a tissue state in an individual, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, (iii) a measure of glycation end-products in tissue, and (iv) a combination of the above, comprising;

(a) determining a fluorescence lifetime of a portion of the skin of the individual;

(b) acquiring biologic information comprising one of more of;

gender of the individual, weight of the individual, waist circumference of the individual, history of disease of the individual'"'"'s family, ethnicity, skin melanin content, smoking history of the individual, or a combination thereof; and

(c) using a multivariate method to determine a tissue state of the individual from the fluorescence lifetime and the biologic information.

7. A method according to claim 6, wherein:

(i) the fluorescence lifetime comprises the intrinsic fluorescence lifetime of the portion of the skin;

(ii) the tissue state comprises the concentration of glycation end-products; and

(iii) using a multivariate method comprises applying a multivariate model relating intrinsic fluorescence lifetime of skin to the concentration of glycation end-products.

8. A method according to claim 6, wherein determining a fluorescence lifetime comprises illuminating the portion of the skin with a short pulse of the excitation light and detecting the fluorescence lifetime by recording the time signature of the fluorescence decay.

9. A method according to claim 6, wherein determining a fluorescent lifetime comprises illuminating the portion of the skin with a modulation of the excitation light and detecting the fluorescence lifetime by recording the amplitude and phase shift of the fluorescence relative to the excitation modulation.

10. A method according to claim 6, wherein determining a fluorescence lifetime comprises using confocal detection or optical coherence tomography to discriminate the tissue depth from which the fluorescence lifetime originates.

11. A method according to claim 6, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, and (iii) a combination of the above.

12. A method according to claim 6, further comprising determining a skin reflectance characteristic at the excitation light wavelength, detecting light returned from the skin in response to illumination at the excitation wavelength, and determining a corrected fluorescence lifetime from the detected light and the skin reflectance characteristic;

and wherein the tissue state is determined from the corrected fluorescence measurement.

13. A method of determining a tissue state of the tissue of an individual, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, (iii) a measure of glycation end-products in tissue, and (iv) a combination of the above, comprising;

(a) illuminating a portion of the tissue of the individual with excitation light;

(b) detecting light emitted from the tissue by fluorescence lifetime of a chemical within the tissue, where the tissue is not the lens of the eye;

(c) determining a tissue reflectance characteristic at an excitation light wavelength;

(d) detecting light returned from the tissue in response to illumination at the excitation wavelength;

(e) determining a corrected fluorescence lifetime from the detected light and the tissue reflectance characteristic;

(f) acquiring biologic information comprising one of more of;

gender of the individual, weight of the individual, waist circumference of the individual, history of disease of the individual'"'"'s family, ethnicity, skin melanin content, smoking history of the individual, or a combination thereof; and

(g) determining the tissue state from the biologic information and the corrected fluorescence lifetime and a model relating biologic information, fluorescence lifetime, and tissue state.

14. A method as in claim 13, wherein the excitation light has a wavelength in the range from 280 nm to 500 nm.

15. A method as in claim 14, wherein the excitation light has a wavelength in the range from 315 nm to 500 nm.

16. A method as in claim 13, wherein detecting light emitted from the tissue comprises detecting light at a wavelength between 280 nm and 850 nm.

17. A method as in claim 13, wherein the fluorescence lifetime is measured in a time-domain mode.

18. A method as in claim 17, wherein the time-domain mode measurement comprises illuminating the portion of the tissue with a short pulse of the excitation light and recording the time signature of the fluorescence decay of the chemical within the tissue.

19. A method as in claim 13, wherein the fluorescence lifetime is measured in a frequency-domain mode.

20. A method as in claim 19, wherein the frequency-domain mode measurement comprises illuminating the portion of the tissue with a modulation of the excitation light and recording the amplitude and phase shift of the fluorescence relative to the excitation modulation of the chemical within the tissue.

21. A method as in claim 13, wherein detecting light comprises determining a relationship between a pulsed or modulated excitation light illumination and fluorescence lifetime at a detection wavelength, and wherein determining tissue state comprises comparing the relationship with a model defining a relationship between tissue state and relationships between the excitation light pulse or modulation and fluorescence lifetime at the detection wavelength.

22. A method as in claim 13, wherein the tissue comprises the skin of the individual.

23. A method as in claim 13, wherein the model is determined according to:

(a) for each of a plurality of subjects;

(i) determining a fluorescence lifetime of a portion of the tissue of the subject;

(ii) acquiring biologic information of the subject; and

(iii) determining a tissue state of the subject; and

(b) applying a multivariate method to the plurality of fluorescence lifetime determinations, biologic information, and associated tissue state determinations to generate a model relating fluorescence lifetime and biologic information to a tissue state.

24. A method according to claim 13, wherein the tissue state comprises the presence of glycation end-products, the concentration of glycation end-products, the change in the concentration of glycation end-products, the presence of glycated collagen, the concentration of glycated collagen, the change in the concentration of glycated collagen, the disease state of the individual, or a combination thereof.

25. A method according to claim 13, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, and (iii) a combination of the above.

26. A method of determining a model relating fluorescence and tissue state, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, (iii) a measure of glycation end-products in tissue, and (iv) a combination of the above, comprising;

(a) for each of a plurality of subjects;

(i) determining a fluorescence lifetime of a portion of the tissue of the subject, where the tissue is not the lens of the eye, by detecting light emitted from the tissue by;

(1) determining a tissue reflectance characteristic at an excitation light wavelength;

(2) detecting light returned from the tissue in response to illumination at the excitation wavelength;

(3) determining a corrected fluorescence lifetime from the detected light and the tissue reflectance characteristic;

(ii) determining a tissue state of the subject;

(iii) acquiring biologic information comprising one of more of;

gender of the individual, weight of the individual, waist circumference of the individual, history of disease of the individual'"'"'s family, ethnicity, skin melanin content, smoking history of the individual, or a combination thereof; and

(b) applying a multivariate method to the plurality of corrected fluorescence lifetime determinations and associated tissue state determinations and associated biologic information to generate a model relating corrected fluorescence lifetime and biologic information to tissue state.

27. A method as in claim 26, wherein determining a fluorescence lifetime of a portion of the tissue of the subject comprises:

a. Illuminating the portion of the tissue of the individual with pulsed or modulated excitation light; and

b. Detecting light emitted from the tissue by fluorescence lifetime of a chemical within the tissue.

28. A method as in claim 26, wherein determining a tissue state comprises at least one of:

(a) evaluating the subject according to OGTT;

(b) evaluating the subject according to an FPG;

(c) evaluating the subject according to an HbA1c test;

(d) determining a previous disease state determination from disease state declared by the subject;

(e) determining a level of glycation endproducts in the tissue of the subject.

29. A method as in claim 26, wherein applying a multivariate method comprises applying a multivariate model constructed according to the Partial Least Squares, Principal Components Regression, Principal Components Analysis, Classical Least Squares, Multiple Linear Regression, Ridge Regression algorithms, Linear Discriminant algorithms, Quadratic Discriminant algorithms, Logistic Regression algorithms, or a combination thereof.

30. A method as in claim 26 wherein the portion of the tissue comprises the skin of the subject.

31. A method according to claim 26, where “

tissue state”

is any of (i) a disease state based on long-term changes (greater than one month duration) in tissue, (ii) a measure of chemical change based on long-term (greater than one month duration) glycemic control, and (iii) a combination of the above.